About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
J
Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Trials
By
Joshua Richter
2 Videos
July 20, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
27:54
Bristol Myers Squibb Hematology
Importance of Maintenance Therapy in MM Patients Post Auto-HSCT
Feat.
B. Randolph
Featured Video
28:15
Bristol Myers Squibb Hematology
Considerations for Continuous Therapy in Multiple Myeloma
Feat.
D. Landau
Related Content
AUTOPLAY
ON
15:24
SOHO 3rd Italian Conference
SOHO Italy 2021 on R/R MM Treatment in Europe
Feat.
C. Cerchione
17:47
SOHO 3rd Italian Conference
SOHO Italy 2021 on MM: State of the Art Therapy in Europe
Feat.
C. Cerchione
01:29
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…
Feat.
C. Cerchione
16:57
SOHO Italy 1st School of Multiple Myeloma
Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …
Feat.
C. Cerchione
06:50
ecancer
EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM
Feat.
C. Cerchione
10:40
Claudio Cerchione
Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT…
19:13
SOHO Italy 1st School of Multiple Myeloma
Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?
Feat.
C. Cerchione
15:57
SOHO 3rd Italian Conference
SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives
Feat.
C. Cerchione
17:29
SOHO Italy 1st Clinical and Biological School of CAR-T
How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma
Feat.
C. Cerchione
26:05
SOHO Italy 1st School of Multiple Myeloma
Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…
Feat.
C. Cerchione
36:30
Bristol Myers Squibb Hematology
A Physician Perspective on Treating NSCT NDMM
Feat.
F. Davies
17:59
Parameswaran Hari
Delivering the Best Initial Treatment for Myeloma: Induction Therapy…
15:12
Yale Cancer Center
ASH 2021: Cellular Therapies in Myeloma
Feat.
N. Bar
10:50
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …
Feat.
A. Jakubowiak
33:28
Cleveland Clinic Taussig Cancer Institute
Management of Relapsed/Refractory Multiple Myeloma
Feat.
F. Anwer
26:18
Morie Gertz
Treatment of Relapsed Myeloma: Overview of Approved Drugs & Opti…
16:00
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…
Feat.
R. Baz
31:15
Claudio Cerchione
R/R MM State of the Art: Proteasome Inhibitors, IMiDs, HDACi, mAbs, …
23:18
Oncology Data Advisor
Can Diet and Nutrition Impact Multiple Myeloma Outcomes?
Feat.
U. Shah,
R. Banerjee
26:02
Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…
Feat.
J. Brayer
